Form 4: Supernus Director Boosts Stake via Option Exercise, RSU Vesting

Supernus Pharmaceuticals Director Georges Gemayel increased his beneficial ownership by acquiring 19,475 shares through option exercise and restricted stock unit vesting.

Summary

• Georges Gemayel, a Director of Supernus Pharmaceuticals, Inc. (SUPN), reported transactions that increased his beneficial ownership of the company's common stock.
• On February 23, 2026, Gemayel exercised a Director Stock Option to acquire 15,000 shares of common stock at an exercise price of $12.98 per share.
• Following this option exercise, his direct beneficial ownership of common stock was 33,684 shares.
• On February 24, 2026, 4,475 restricted stock units (RSUs) vested and were settled into common stock, which were acquired at a price of $0.
• The vesting of these RSUs occurred on February 19, 2026, with settlement following shortly thereafter.
• After both the option exercise and RSU settlement, Gemayel's total direct beneficial ownership of Supernus common stock stands at 38,159 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director increasing their stake, even through compensation-related transactions, generally indicates continued alignment with shareholder interests and confidence in the company's future.

Positives

• A Director increasing their stake in the company, even through compensation-related mechanisms, can signal confidence in the company's future performance.
• The exercise of stock options and vesting of RSUs are standard components of executive and director compensation, aligning their financial interests with those of shareholders.

Negatives

• No explicit negatives are present in this Form 4 filing, which primarily reports statutory insider transactions.

Risks

• This Form 4 filing is a report of insider transactions and does not contain information regarding company-specific risks or challenges.

Future Outlook

The filing does not contain forward-looking statements or guidance, as it is a report of past insider transactions.

Industry Context

StockSavvy.ai notes that insider buying, even through option exercises and RSU vesting, can sometimes be interpreted by the market as a positive signal, indicating management's belief in the company's prospects. This is a routine compliance filing for a director of a pharmaceutical company.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all publicly traded companies in the U.S.
• There are no specific industry benchmarks for the volume or type of insider transactions reported, as they are individual compensation and investment decisions.
• The exercise of options and vesting of RSUs are common forms of executive and director compensation in the pharmaceutical industry, similar to practices at companies like Pfizer or Johnson & Johnson.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive sign of confidence in the company's future performance.
• The transactions are part of the director's compensation structure, aligning their financial interests with the company's success.

Next Steps

• The filing does not mention any specific future actions, events, or milestones beyond the reported transactions.

Key Dates

Recommendation

While the director's increased stake is a positive signal of confidence, a Form 4 filing alone does not provide sufficient fundamental information to warrant a 'buy' recommendation. It primarily reports a routine insider transaction related to compensation. Investors should 'hold' and consider this information in conjunction with broader financial performance, strategic outlook, and market conditions for Supernus Pharmaceuticals.

Keywords

Supernus Pharmaceuticals, SUPN, Form 4, Insider Trading, Stock Option Exercise, Restricted Stock Units, Director Stock, Beneficial Ownership